Hospital
Clay County Medical Corporation
Clay County Medical Corporation was paid $16.13M by Medicaid between Jan 2018 and Dec 2024, across 213 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoCLAY COUNTY MEDICAL CORPORATION
WEST POINT, MS 39773
WEST POINT, MS 39773
33aNPI1639284409assigned 08/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.13M
24GClaims433,536
24DCodes billed213
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#32 of 77
Median peer was paid$8.23M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TOPPIN, BRUCE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,310 | $2.13M | |
| 2019 | 55,175 | $2.23M | |
| 2020 | 48,298 | $1.80M | |
| 2021 | 57,254 | $2.34M | |
| 2022 | 73,691 | $2.80M | |
| 2023 | 79,305 | $2.66M | |
| 2024incomplete | 64,503 | $2.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 16,221 | 13,810 | $3.27M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 18,025 | 15,264 | $2.56M |
| G0378 | Hospital observation service, per hour | 7.5% | 3,318 | 2,440 | $1.20M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 3,475 | 2,986 | $800K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.9% | 7,565 | 6,105 | $792K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 7,681 | 6,321 | $613K |
| 87428 | 3.3% | 9,512 | 8,345 | $535K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.0% | 13,348 | 9,723 | $481K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.3% | 6,403 | 4,304 | $376K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 3,485 | 2,590 | $350K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 1,942 | 1,702 | $312K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 7,092 | 6,011 | $287K |
201 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.6% | 2,731 | $258K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.3% | 15,991 | $216K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 7,331 | $213K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 1,876 | $212K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.3% | 1,623 | $211K |
| 80053 | Comprehensive metabolic panel | 1.1% | 25,974 | $176K |
| 86885 | 1.1% | 2,040 | $173K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 3,798 | $163K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,512 | $158K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,908 | $158K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,904 | $158K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,889 | $152K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,019 | $151K |
| 86900 | <1% | 2,370 | $150K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,670 | $147K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,244 | $144K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,963 | $129K |
| 54161 | <1% | 59 | $84K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 668 | $71K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 826 | $65K |
| 86901 | <1% | 2,615 | $52K | |
| 74018 | <1% | 1,146 | $51K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 660 | $51K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 730 | $47K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,612 | $47K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,805 | $44K |
| 87400 | <1% | 2,284 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,642 | $40K |
| 74019 | <1% | 586 | $39K | |
| 83880 | <1% | 1,890 | $38K | |
| 87070 | <1% | 4,262 | $34K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 719 | $33K |
| 84484 | <1% | 5,168 | $33K | |
| 81001 | <1% | 14,568 | $32K | |
| 87420 | <1% | 2,495 | $32K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 817 | $31K |
| 86703 | <1% | 3,083 | $31K | |
| 80061 | Lipid panel | <1% | 3,008 | $29K |
| 81025 | <1% | 3,733 | $24K | |
| 87807 | <1% | 2,103 | $23K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,252 | $23K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,638 | $20K |
| 83690 | <1% | 4,866 | $20K | |
| 83735 | <1% | 4,899 | $19K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 943 | $17K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,444 | $17K |
| 82728 | <1% | 2,319 | $16K | |
| 96367 | <1% | 528 | $15K | |
| 87799 | <1% | 166 | $14K | |
| 87186 | <1% | 2,135 | $13K | |
| 82607 | <1% | 1,554 | $13K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 269 | $13K |
| 83655 | <1% | 1,184 | $13K | |
| 84702 | <1% | 1,189 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,760 | $12K |
| 73562 | <1% | 339 | $12K | |
| 87481 | <1% | 172 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 241 | $12K |
| 80306 | <1% | 928 | $12K | |
| 87340 | <1% | 1,548 | $11K | |
| Q3014 | Telehealth originating site facility fee | <1% | 662 | $11K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 57 | $11K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 163 | $11K |
| 86803 | <1% | 1,062 | $11K | |
| 86592 | <1% | 3,074 | $10K | |
| 59025 | Fetal non-stress test | <1% | 100 | $10K |
| 88142 | <1% | 593 | $9K | |
| 86762 | <1% | 802 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 33 | $8K |
| 87077 | <1% | 1,545 | $8K | |
| 82553 | <1% | 1,309 | $8K | |
| 83550 | <1% | 2,045 | $8K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 292 | $7K |
| 87040 | <1% | 1,292 | $7K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 370 | $7K |
| 83540 | <1% | 2,106 | $6K | |
| 73610 | <1% | 140 | $6K | |
| 73030 | <1% | 171 | $6K | |
| 83020 | <1% | 667 | $6K | |
| 82746 | <1% | 811 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 79 | $6K |
| 84703 | <1% | 1,125 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 77 | $6K |
| 83605 | <1% | 1,071 | $6K | |
| 85018 | <1% | 2,739 | $5K | |
| 85014 | <1% | 2,735 | $5K | |
| 85027 | <1% | 908 | $5K | |
| 87512 | <1% | 165 | $5K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 17 | $4K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 68 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 165 | $4K |
| 82150 | <1% | 571 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,790 | $4K |
| 72100 | <1% | 75 | $4K | |
| 85610 | <1% | 1,463 | $3K | |
| 87081 | <1% | 679 | $3K | |
| 86140 | <1% | 880 | $3K | |
| 83021 | <1% | 217 | $3K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 15 | $3K |
| 73130 | <1% | 60 | $3K | |
| 81003 | <1% | 834 | $3K | |
| 77336 | <1% | 77 | $2K | |
| 82570 | <1% | 674 | $2K | |
| 84153 | <1% | 210 | $2K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 17 | $2K |
| 73630 | <1% | 47 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,936 | $2K |
| 36600 | <1% | 29 | $2K | |
| 82962 | <1% | 1,061 | $2K | |
| 82378 | <1% | 173 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,840 | $2K |
| 85379 | <1% | 215 | $1K | |
| 73560 | <1% | 39 | $1K | |
| 84156 | <1% | 536 | $1K | |
| 83615 | <1% | 319 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 276 | $1K |
| 73502 | <1% | 41 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,538 | $1K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 19 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,362 | $1K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $1K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 62 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 46 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,066 | $963.13 |
| 97162 | <1% | 29 | $938.83 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $935.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 26 | $925.65 |
| 82784 | <1% | 91 | $888.04 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,742 | $838.38 |
| 97161 | <1% | 15 | $804.55 | |
| 73110 | <1% | 12 | $747.74 | |
| 87210 | <1% | 232 | $731.51 | |
| 85730 | <1% | 329 | $710.80 | |
| 85652 | <1% | 452 | $698.90 | |
| 96376 | <1% | 2,212 | $688.42 | |
| 84439 | <1% | 124 | $674.07 | |
| 82947 | <1% | 242 | $653.44 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 33 | $645.23 |
| 82948 | <1% | 158 | $628.34 | |
| 80305 | <1% | 66 | $626.44 | |
| 82803 | <1% | 34 | $563.50 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,031 | $530.51 |
| 36591 | <1% | 978 | $530.30 | |
| 85041 | <1% | 390 | $528.00 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 16 | $519.96 |
| 84165 | <1% | 107 | $485.24 | |
| 85044 | <1% | 209 | $414.31 | |
| 85651 | <1% | 99 | $413.70 | |
| 82550 | <1% | 144 | $391.83 | |
| 71250 | <1% | 12 | $363.70 | |
| 84403 | <1% | 17 | $232.76 | |
| A9270 | Non-covered item or service | <1% | 2,696 | $222.66 |
| 82565 | <1% | 44 | $190.78 | |
| 82044 | <1% | 36 | $175.92 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,739 | $160.90 |
| 86038 | <1% | 24 | $160.52 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,350 | $119.84 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,633 | $113.24 |
| 86334 | <1% | 13 | $111.75 | |
| 84100 | <1% | 76 | $98.41 | |
| 82247 | <1% | 22 | $91.61 | |
| 84550 | <1% | 26 | $85.55 | |
| 82043 | <1% | 25 | $82.94 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 284 | $67.55 |
| 82272 | <1% | 27 | $61.40 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,183 | $56.19 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 103 | $54.55 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,436 | $43.64 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 43 | $41.30 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,759 | $40.92 |
| 84155 | <1% | 63 | $39.60 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 768 | $35.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 558 | $22.42 |
| 85045 | <1% | 16 | $22.34 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 755 | $20.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,107 | $19.69 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 310 | $19.18 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,690 | $11.62 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 419 | $3.71 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 70 | $0.23 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 72 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 106 | $0.00 |
| 84145 | 0% | 54 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 66 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 21 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 28 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 31 | $0.00 |
| 00920 | 0% | 32 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 86 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 52 | $0.00 |
| 81329 | 0% | 60 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 335 | $0.00 |
| 80050 | General health panel | 0% | 31 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 37 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 530 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 182 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 155 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 17 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 16 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 91 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTOPPIN, BRUCE (CORPORATE SECRETARY)
Parent organizationCLAY COUNTY MEDICAL CORPORATION
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.